Nouvelle déclaration d'incident
No de la demande: 2020-4264
Numéro de référence du titulaire d'homologation: 2020-US-010779
Nom du titulaire (nom légal complet, aucune abbréviation): Wellmark International
Adresse: 100 Stone Road West, Suite 111
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G5L3
Incident chez un animal domestique
Pays: UNITED STATES
État: WASHINGTON
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2724-829-89459
Nom du produit: Adams Pentagon Flea And Tick Spot On For Dogs
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Cat / Chat
Unknown
1
Inconnu
Inconnu
Inconnu
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On the afternoon or evening of 5-May-2020 the product was applied to the cat. This cat died at an unspecified time 6-May-2020. No further information is available.
Mort
Assessment: Etofenprox, a non-ester pyrethroid, and the other ingredients present in this product are considered to have a good safety margin in cats. As with application of any topical product individual sensitivities may occur. This product is not labelled for use on cats. However severe adverse effects including death are not expected, even with off label use. Other causes should be considered including exposure to a permethrin containing canine flea and tick product, other toxic exposure, underlying disease, and infection. Necropsy may have provided additional information but was not pursued by the animal owner. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.